...
首页> 外文期刊>Phytomedicine : >In vivo anti-diabetic, antioxidant and molecular docking studies of 1, 2, 8-trihydroxy-6-methoxy xanthone and 1, 2-dihydroxy-6-methoxyxanthone-8-O-β- d-xylopyranosyl isolated from Swertia corymbosa
【24h】

In vivo anti-diabetic, antioxidant and molecular docking studies of 1, 2, 8-trihydroxy-6-methoxy xanthone and 1, 2-dihydroxy-6-methoxyxanthone-8-O-β- d-xylopyranosyl isolated from Swertia corymbosa

机译:分离自Swertia corymbosa的1、2、8-三羟基-6-甲氧基黄酮和1,2-二羟基-6-甲氧基黄酮-8-O-β-d-吡喃吡喃糖基的体内抗糖尿病,抗氧化剂和分子对接研究

获取原文
获取原文并翻译 | 示例

摘要

1, 2, 8-trihydroxy-6-methoxy xanthone (1) and 1, 2- dihydroxy-6- methoxyxanthone-8-O-β-d-xylopyranosyl (2) are the main constituents of petroleum ether and ethyl acetate extracts from Swertia corymbosa (Gentinaceae), a medicinal plant used in Indian traditional system for the treatment of diabetes. The present study was designed to examine the antihypoglycemic, antihyperlipidemic and antioxidant effect of compounds 1 and 2 in streptozotocin (STZ) induced diabetic rats. Diabetes was induced in male Wistar rats by a single intraperitoneal injection of STZ (60 mg/kg b.w.). The isolated compounds 1 and 2 at a dose of 50 mg/kg b.w., produced the maximum fall of 83% in the blood glucose level in the diabetic rats after 3 h of the treatment. The administration of 1 and 2 (50 mg/kg b.w.) daily for 28 days in STZ induced diabetic rats, resulted in a significant decrease in blood glucose, glycosylated hemoglobin, SGOT, SGPT, ALP serum urea and creatinine with significant rise in plasma insulin level. Test compounds 1 and 2 showed antihyperlipidemic activities as evidenced by significant decrease in serum TC, TG, LDL-C, VLDL-C levels coupled together with elevation of HDL-C level in diabetic treated rats when compared to diabetic untreated rats, indicate the protective role against liver and kidney damage. The results of histopathology also showed 1 and 2 protected tissues (pancreas, liver and kidney) against peroxidation damage and maintained tissue integrity. Further, the molecular interaction study of the ligands 1, 2 and glibenclamide with various diabetes mellitus related protein targets like glucokinase (PDB ID: 1V4S), fructose-1, 6-bisphosphatase 1 (PDB ID: 2JJK) 11-β-hydroxysteroid dehydrogenase (PDB ID: 2BEL) and modeled protein sulfonylurea receptor 1 (SUR1) showed that ligand 1 and 2 possess binding affinity with all protein targets except for 2BEL target protein for which ligand 1 has no interaction. The ligand pose with 2BEL and SUR1 protein target of ligand 2 gave the best binding conformation. Hence 1 and 2 can be considered for developing into a potent antidiabetic drug.
机译:1,2,8,8-三羟基-6-甲氧基黄酮(1)和1,2-二羟基-6-甲氧基黄酮8-O-β-d-吡喃吡喃糖基(2)是石油醚和乙酸乙酯提取物中的主要成分Swertia corymbosa(Gentinaceae),印度传统系统中用于治疗糖尿病的药用植物。本研究旨在检查化合物1和2在链脲佐菌素(STZ)诱导的糖尿病大鼠中的抗降血糖,抗高血脂和抗氧化作用。腹膜内注射STZ(60 mg / kg b.w.)在雄性Wistar大鼠中诱发糖尿病。治疗3小时后,以50mg / kg b.w.的剂量分离的化合物1和2使糖尿病大鼠的血糖水平最大降低83%。在STZ诱导的糖尿病大鼠中每天1和2(50 mg / kg bw)的给药持续28天,导致血糖,糖基化血红蛋白,SGOT,SGPT,ALP血清尿素和肌酐的显着降低,血浆胰岛素显着升高水平。与糖尿病未治疗的大鼠相比,试验化合物1和2显示出抗高血脂活性,这由糖尿病治疗的大鼠的血清TC,TG,LDL-C,VLDL-C水平显着降低以及HDL-C水平升高所证明。抗肝肾损害作用。组织病理学结果还显示,有1和2个受保护的组织(胰腺,肝和肾)免于过氧化损伤,并保持了组织的完整性。此外,配体1、2和格列本脲与各种糖尿病相关蛋白靶标的分子相互作用研究,例如葡萄糖激酶(PDB ID:1V4S),果糖-1、6-双磷酸酶1(PDB ID:2JJK)11-β-羟基类固醇脱氢酶(PDB ID:2BEL)和建模的蛋白质磺酰脲受体1(SUR1)表明,配体1和2与所有蛋白质靶标都具有结合亲和力,除了配体1没有相互作用的2BEL靶标蛋白。具有2BEL和配体2的SUR1蛋白靶的配体姿势给出了最佳的结合构象。因此,可以考虑将1和2开发成有效的抗糖尿病药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号